About this template
A Phase II clinical trial is one long chain of gates: no participant gets screened before ethics and regulatory approval land, no patient gets dosed before the site is trained and supplied, and no analysis happens before the database is locked. This 18-month template lays out a realistic Phase II timeline — protocol and statistical plan, IRB/ethics and regulatory filing, site activation and recruitment, the treatment and monitoring period, an interim analysis, and the final push from last patient out to the clinical study report. It is a project-scheduling tool, not medical guidance — use it to plan operations and timelines, and rely on your protocol and regulatory team for the science. Open it and drag any bar to fit your actual dates.
How an 18-month Phase II trial breaks down
Months 1–3 — Design and planning
Everything downstream depends on what gets locked here. The protocol defines eligibility, dosing, endpoints, and the visit schedule; the statistical analysis plan defines exactly how the data will be analyzed before anyone sees results, which protects the trial from post-hoc bias. CRO and core vendor selection (lab, imaging, drug supply) should start in parallel with protocol drafting, not after it — vendor contracts take weeks to negotiate. Case report forms and trial registration close out the phase.
- Draft and finalize the protocol
- Write the statistical analysis plan
- Select the CRO and core vendors
- Design the case report forms
- Register the trial before recruitment opens
Months 3–4 — Regulatory and ethics approval
Two approvals gate everything that follows: the IRB or ethics committee, and the regulatory authority (an IND in the US, a CTA in the EU/UK). Submit both as close together as the protocol allows, since reviewers frequently return questions that need a coordinated response. Budget 4–6 weeks for initial IRB review, longer if the committee only meets monthly. Approval is the hard gate — no site can screen a single participant before it lands.
- Submit to the IRB or ethics committee
- File with the regulatory authority (IND/CTA)
- Respond to reviewer questions
- Receive IRB/ethics approval
- Charter the data safety monitoring board
Months 4–7 — Site activation and recruitment
With approval in hand, the trial becomes physical: sites are qualified and contracted, investigators and coordinators are trained on the protocol and the data capture system, and investigational product ships under proper chain-of-custody and temperature control. Recruitment then opens, and screening runs against the protocol's inclusion and exclusion criteria — expect 2–4 screen failures for every participant who is randomized. The first patient enrolled is the trial's real start date, whatever the calendar says.
- Qualify and contract trial sites
- Train investigators and site coordinators
- Ship investigational product to sites
- Open recruitment and screen participants
- Enroll the first patient
Months 7–16 — Treatment, monitoring, and interim analysis
This is the long middle of the trial: participants are dosed on schedule, monitors visit sites regularly to verify source data and check protocol compliance, and adverse events are logged and reported on regulatory timelines. Partway through, a pre-specified interim analysis lets the data safety monitoring board check for early efficacy or safety signals without unblinding the study team. The phase ends only when the last enrolled patient completes their final protocol visit.
- Dose and monitor enrolled participants
- Run scheduled monitoring visits
- Report adverse events on regulatory timelines
- Conduct the interim analysis
- Complete the final visit for the last patient
Months 16–18 — Database lock and final reporting
Once the last visit is complete, priority shifts to data quality: outstanding queries get resolved with sites, and the database is locked so no further changes are possible. Only after lock does the biostatistics team run the pre-specified analysis from the statistical analysis plan — locking first is what keeps the result credible. The clinical study report then packages the methods, results, and conclusions for regulatory submission, publication, or both.
- Resolve outstanding data queries
- Lock the database
- Run the statistical analysis
- Draft the clinical study report
- Deliver the final study report
Tips from real trial timelines
- Lock the statistical analysis plan before anyone sees the data — amending it after an interim look invites regulatory scrutiny and can undermine the trial's credibility.
- Start site contracting the day the protocol is stable, not after ethics approval lands. Contract negotiation often takes as long as the ethics review itself.
- Budget for 2–4 screen failures per randomized participant when planning recruitment timelines. Undercounting this is the most common cause of enrollment delays.
- Fix the data safety monitoring board's meeting schedule before the trial starts. Scheduling it around interim analyses as you go is where timelines slip.
- Resolve data queries continuously instead of in an end-of-trial scramble. A clean database at last patient out can shave weeks off the database lock.
Frequently asked questions
How long does a Phase II trial actually take?
Most Phase II trials run 1–3 years depending on indication, sample size, and how fast participants are recruited. This 18-month template assumes a moderate sample size with a manageable screen-failure rate.
What is the biggest driver of delay in a clinical trial?
Recruitment. Slow enrollment is the single most common reason trials run long — sites routinely take twice as long to hit enrollment targets as originally planned.
Can I open this template and customize it?
Yes. Click "Open this template in the app" — it loads instantly, and you can drag, rename, and re-color every task. The app runs entirely in your browser. Your data never leaves the device.